NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
HDFC Securities Institutional Equities
We initiate Jyothy Laboratories Ltd. with a high conviction Buy idea, with a target price of Rs 575 (40 times June-26 EPS), as it is one of the few FMCG companies structurally poised for high single-digit volume growth, mid-teen Ebitda growth, and high-teen net income growth. We pencil in revenue/Ebitda/profit after tax compound annual growth rate of 12/16/17% over FY24-27, the second highest amongst our coverage of consumer staple companies.
Our confidence stems from the fact that
it operates in categories which have a higher Total Addressable Market and, despite being a challenger brand, is trying to grab a pie of the same via making the product portfolio comprehensive, launching low unit packs, communicating product superiority vs. competition, and providing -for-money offerings;
doing basics of FMCG right under new leadership- increasing the distribution network and, at the same time, improving productivity; moving on to Above the Line spends, away from BTL spends; focusing on low unit packs across the product portfolio, so that it aligns with the above-mentioned objectives;
competent key management personnel are ensuring smooth execution of the above strategy, which was not the case with the erstwhile management, who were more tuned towards doing M&A transactions.
Reasonable valuations (32 times FY26 earnings per share) provide a significant margin of safety. We call Jyothy Labs sarva gunn sampann – fully versatile and with enough weapons in its armory to combat any challenge.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
RECOMMENDED FOR YOU
![](https://images.assettype.com/bloombergquint/2024-06/2a4036fe-3263-423d-b0fb-f38d605251c5/HCLTech_Photo.jpg?rect=0%2C0%2C3500%2C1969&auto=format%2Ccompress&format=webp&w=75)
HCLTech To Launch Private 5G Solution With HPE, Set Up Lab In Noida
![timelogo](/images/amp-time.png)
![](https://images.assettype.com/bloombergquint/2023-10/a4838768-72b1-438b-b4f2-b84f838c80ae/Exterior_view_of_New_SEBI_signage__logo_at_office_building_in_BKC__Bandra_Kurla_Complex___Source_Vij.jpeg?rect=0%2C0%2C3500%2C1969&auto=format%2Ccompress&format=webp&w=75)
SEBI Restricts Secur Credentials And Its MD From Securities Market
![timelogo](/images/amp-time.png)
![](https://images.assettype.com/bloombergquint/2022-07/60202210-1ee3-436c-8c1d-c9aaee2fbc54/A_researcher_testing_a_chemical_solution_inside_a_lab___Source_freepik_.png?rect=0%2C0%2C3500%2C1969&auto=format%2Ccompress&format=webp&w=75)
Kronox Lab Science IPO - Investment Rationale, Issue Details, Financials, Risks And More: Anand Rathi
![timelogo](/images/amp-time.png)
![](https://images.assettype.com/bloombergquint/2021-05/58fb2a8c-789c-46e1-aa33-46431e0b8f3d/Alkem_Labs_R_D_fcility___Source_Company_website_.png?rect=0%2C0%2C3500%2C1969&auto=format%2Ccompress&format=webp&w=75)
Alkem Lab Q4 Results: Net Profit Surges Four-Fold To Rs 293 Crore
![timelogo](/images/amp-time.png)